      Nathan Fischel - DAFNA Capital Management - 2017 Stock Picks and Performance - Insider Monkey                          Companies 0 See All     Hedge Funds 0 See All    Insiders 0 See All    Institutional Investors 0 See All   Click here to see all  results for  Sorry, no results has been found matching your query.                   Adblocker Detected    Dear Valued Visitor, We have noticed that you are using an ad blocker software.
    Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages. To view this article, you can disable your ad blocker and refresh this page or simply login. We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.       Home > Hedge Funds > DAFNA Capital Management
				> Profile    Hedge Fund - DAFNA Capital Management  Get Email Alerts     Profile Holdings Latest 13D & 13G Filings News, Interviews, and Investor Letters     Get Email Alerts  Profile Holdings Latest 13D & 13G Filing News     Nathan Fischel Bio, Returns, Net Worth     DAFNA Capital Management is founded by Nathan Fischel in January 1999. Nathan Fischel is an M.D. and manages the hedge fund with his wife Fariba Ghodsian who has a Ph.D. in Biomedical Engineering from Oxford University. DAFNA Capital makes fundamental and event-driven long and short bets in biotech and medical device companies.                    Fund Profile  Filing Period:  2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31          Fund Name: DAFNA Capital Management   Manager Nathan Fischel   Portfolio Value $118,230,000   Change This QTR +1.04%                 Top Holdings  Login to See All Holdings | Sign up      Filing Period:  2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31     Last updated on May 15, 2017, 4:09 pm based on SEC 13F filings Last update: May 15, 2017, 4:09 pm              No.  Security  Ticker  Shares  Value (x$1000)  Activity  % Port      1. Loxo Oncology Inc. LOXO 300,722 $12,654 +116% 10.7%   2. Atricure Inc. ATRC 506,946 $9,708 -3% 8.21%   3. Nxstage Medical Inc. NXTM 216,119 $5,798 -9% 4.9%   4. Alder Biopharmaceuticals Inc ALDR 221,013 $4,597  3.88%   5. Biocryst Pharmaceuticals Inc BCRX 541,128 $4,545 +722% 3.84%        Login to See All Holdings | Sign up, It's FREE        Latest 13D & 13G Filings  Login to See All Filings | Sign up       Company Symbol Filed By Filing Date Filing    Stereotaxis Inc. STXS DAFNA Capital Management 2017-02-14 13D Filing   Windtree Therapeutics Inc WINT DAFNA Capital Management 2017-02-14 13G Filing   Sunesis Pharmaceuticals Inc SNSS DAFNA Capital Management 2017-02-14 13G Filing   Encision Inc ECIA DAFNA Capital Management 2017-02-14 13G Filing       Login to See All Filings | Sign up, It's FREE       News, Interviews and Investor Letters See All         The Stock Picks of This Obscure Hedge Fund Returned 70.5% In 2015; See What It’s Betting On in 2016 Although Los Angeles-based, biotech-focused hedge fund DAFNA Capital Management has been in operation for the past 17 years, chances are that very few people have heard its name. However, this obscure...... (read more) March 1st, 2016 -  Hedge Fund Analysis Hedge Funds News - Comments         Under-the-Radar Hedge Fund Focusing on Pharmacyclics, Inc. (PCYC), Novadaq Technologies Inc. (NVDQ) Hedge funds are typically thought of as being billion dollar funds managed by Harvard MBAs and alums of some of Wall Street’s more prestigious analyst programs (i.e. Goldman Sachs, JP Morgan).  Interestingly...... (read more) March 18th, 2013 -  Hedge Funds - Comments       Click here to See All News           Hedge Fund Resource Center    How to Beat the Market by 20 Percentage Points Why Track Hedge Funds? Download a Free Edition! Why You Should DUMP Your Hedge Funds 6 Things You Didn't Know About Hedge Funds        Billionaire Hedge Funds          Warren Buffett Berkshire Hathaway $147,985,198,000          David Einhorn Greenlight Capital $5,818,885,000          George Soros Soros Fund Management $4,321,285,000          T Boone Pickens BP Capital $318,631,000          Jim Simons Renaissance Technologies $63,208,016,000          Leon Cooperman Omega Advisors $2,269,539,000          Carl Icahn Icahn Capital LP $22,373,522,000          Steve Cohen Point72 Asset Management $14,303,015,000          John Paulson Paulson & Co $7,934,312,000          David Tepper Appaloosa Management LP $5,640,040,000              Home Hedge Funds Markets Blog Authors About Us Contact Us Privacy Policy Terms of Use Site Map  All text and design is copyright ©2016 Koala Guide LLC. All rights reserved.             













Bing Places for Business
























































































































Bing
 places for business


Sign in using your




Microsoft Account





Work Account





Google Account





Facebook Account

Don't have an account? Create one.








						Dafna Capital Management Has Cut By $1.44 Million Its Synergy Pharmaceuticals (SGYP) Holding; Tivo (TIVO) Shorts Increased By 24.51% - Norman Observer								

 


















 

























 






















Trending Stock News
Penny Stock News
Market News
Stock News
Contact Us






Dafna Capital Management Has Cut By $1.44 Million Its Synergy Pharmaceuticals (SGYP) Holding; Tivo (TIVO) Shorts Increased By 24.51%


					
						July 25, 2017 - By marketbeat

Dafna Capital Management Llc decreased Synergy Pharmaceuticals (SGYP) stake by 87.62% reported in 2016Q4 SEC filing. Dafna Capital Management Llc sold 240,563 shares as Synergy Pharmaceuticals (SGYP)’s stock declined 35.42%. The Dafna Capital Management Llc holds 34,000 shares with $207,000 value, down from 274,563 last quarter. Synergy Pharmaceuticals now has $946.97M valuation. The stock decreased 2.10% or $0.09 during the last trading session, reaching $4.19. About 2.87M shares traded. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has risen 24.44% since July 25, 2016 and is uptrending. It has outperformed by 7.74% the S&P500.
 Tivo Corporation (NASDAQ:TIVO) had an increase of 24.51% in short interest. TIVO’s SI was 2.48M shares in July as released by FINRA. Its up 24.51% from 2.00M shares previously. With 782,100 avg volume, 3 days are for Tivo Corporation (NASDAQ:TIVO)’s short sellers to cover TIVO’s short positions. The SI to Tivo Corporation’s float is 2.12%. The stock decreased 0.26% or $0.05 during the last trading session, reaching $19.3. About 483,111 shares traded. TiVo Corp (NASDAQ:TIVO) has declined 1.91% since July 25, 2016 and is downtrending. It has underperformed by 18.61% the S&P500.






TiVo Corporation is engaged in offering media and entertainment products. The company has market cap of $2.34 billion. The Firm operates through two divisions: Intellectual Property Licensing and Product. It has a 72.26 P/E ratio. The Company’s Product segment includes a suite of component technologies that can be integrated into media service well-known provider internally developed platforms or deployed as an integrated TiVo solution.
Among 8 analysts covering TiVo (NASDAQ:TIVO), 2 have Buy rating, 0 Sell and 6 Hold. Therefore 25% are positive. TiVo had 11 analyst reports since September 8, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Friday, September 11 by Barrington Research. The rating was downgraded by M Partners on Wednesday, June 1 to “Neutral”. Topeka Capital Markets downgraded TiVo Corp (NASDAQ:TIVO) rating on Monday, May 2. Topeka Capital Markets has “Hold” rating and $11 target. The stock of TiVo Corp (NASDAQ:TIVO) has “Buy” rating given on Friday, July 7 by Jefferies. The company was maintained on Wednesday, November 25 by M Partners. The firm has “Market Perform” rating by Albert Fried given on Monday, May 2. Piper Jaffray maintained TiVo Corp (NASDAQ:TIVO) on Tuesday, May 30 with “Buy” rating. The stock of TiVo Corp (NASDAQ:TIVO) earned “Mkt Perform” rating by FBR Capital on Wednesday, September 9. Barrington Research downgraded TiVo Corp (NASDAQ:TIVO) on Wednesday, November 25 to “Mkt Perform” rating. The firm earned “Buy” rating on Tuesday, September 8 by Topeka Capital Markets.
Since May 26, 2017, it had 2 insider purchases, and 0 selling transactions for $43,302 activity. Another trade for 6,500 shares valued at $23,335 was bought by BRANCACCIO JOHN P. 5,680 Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares with value of $19,967 were bought by JACOB GARY S.
Among 7 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 6 have Buy rating, 1 Sell and 0 Hold. Therefore 86% are positive. Synergy Pharmaceuticals had 17 analyst reports since August 25, 2015 according to SRatingsIntel. BTIG Research maintained the stock with “Buy” rating in Monday, June 26 report. On Thursday, October 29 the stock rating was reinitiated by Roth Capital with “”. BTIG Research initiated Synergy Pharmaceuticals Inc (NASDAQ:SGYP) on Tuesday, August 25 with “Buy” rating. Rodman & Renshaw maintained the stock with “Buy” rating in Friday, December 23 report. Citigroup maintained Synergy Pharmaceuticals Inc (NASDAQ:SGYP) rating on Wednesday, March 16. Citigroup has “Neutral” rating and $4 target. The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) earned “Buy” rating by Rodman & Renshaw on Friday, January 20. The firm earned “Neutral” rating on Friday, December 18 by Citigroup. The firm has “Buy” rating by Cantor Fitzgerald given on Thursday, June 1. The firm has “Buy” rating by H.C. Wainwright given on Monday, June 12. Citigroup downgraded Synergy Pharmaceuticals Inc (NASDAQ:SGYP) on Thursday, April 6 to “Sell” rating.
Analysts await Synergy Pharmaceuticals Inc (NASDAQ:SGYP) to report earnings on August, 14. They expect $-0.22 earnings per share, up 4.35% or $0.01 from last year’s $-0.23 per share. After $-0.30 actual earnings per share reported by Synergy Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -26.67% EPS growth. 
Dafna Capital Management Llc increased Alder Biopharmaceuticals Inc (NASDAQ:ALDR) stake by 55,700 shares to 221,013 valued at $4.60 million in 2016Q4. It also upped Applied Genetic Technol Corp (NASDAQ:AGTC) stake by 46,000 shares and now owns 286,298 shares. Radius Health Inc (NASDAQ:RDUS) was raised too. 



Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.












 




Free Email Newsletter Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:






  Recent Posts 

GMP FirstEnergy Kept Encana (ECA) As Buy; Has PT Of $13.0000, Sina (SINA) SI Increased By 7.79%


Paypal Holdings (PYPL) Investors: Cantor Fitzgerald Reiterates Buy Rating, Sees $70.0000/Share; Delta Air Lines (DAL) Has 0.73 Sentiment


S&Co Has Lifted Cameco Com (CCJ) Stake By $338,400; Sifco Industries (NYSEMKT:SIF) Shorts Up By 84.62%


$-0.13 EPS Expected for Evolent Health (EVH), Sientra (SIEN) SI Decreased By 15.77%


$1.30 EPS Expected for Esterline Technologies (ESL), Last Week Rambus Inc. (RMBS) Analysts


Spirit Airlines (SAVE) Received Imperial Capital Lower Rating, Bank Of New York Co (BK) Sentiment Is 0.97


Parkwood Cut Nabors Industries LTD (NBR) Stake, 1 Analysts Are Bullish DHI Group (DHX) Last Week


KeyBanc Ups LogMeIn (LOGM) To “Overweight” from “Sector Weight”, Shorts at Sears Holdings (SHLD) Lowered By 5.61%


$0.29 EPS Expected for Callaway Golf Co (ELY); ConnectOne Bancorp (CNOB) Covered By 4 Bullish Analysts Last Week


Parkwood Lifted By $702,630 Its Cisco Systems (CSCO) Position, Zimmer Partners LP Has Cut Digitalglobe (DGI) Position By $10.08 Million






© Copyright 2011-2017 Norman Observer
				
			

		












            	Get the Next Big Winner in your inbox Before the Bell



            
Lists*Consumer Eagle







Twitter Auto Publish Powered By : XYZScripts.com


















Dafna Capital Management  Llc in Los Angeles, CA 90024 - ChamberofCommerce.com




   =     


        









Sign Up
Sign In
Contact Us


 














Search
 

near
 













Home
» California
» Los Angeles
» Portfolio Management & Investment Services
» Dafna Capital Management  Llc













Dafna Capital Management  Llc


0 Reviews

0.0000 stars - based on 0 reviews
                            





10990 Wilshire Blvd Ste 1400 Los Angeles, California 90024


(310) 954-3200
Website


 



 

Print |
                Save |
                Directions


About
Dafna Capital Management  Llc is located at the address 10990 Wilshire Blvd in Los Angeles, California 90024.  They can be contacted via phone at (310) 954-3200 for pricing, hours and directions.  Dafna Capital Management  Llc has an annual sales volume of 0 - 500K.  .For more information contact Daniel  Asher, Portfolio Manager or  go to www.dafnacapital.comDafna Capital Management  Llc provides Long Term Planning, Investment Services, College Funding to it's customers.  For maps and directions to Dafna Capital Management  Llc view the map to the right.  For reviews of Dafna Capital Management  Llc see below.









Business Features

PRODUCTS


Employer-Sponsored Pensions
, Tax Free Investments
, Real Estate Mutual Funds
, Stocks
, Group Policies
, Treasury Bonds
, Profit Sharing Plans
, Short-Term Policies
, Individual Policies
, Business Continuation Plans



SERVICES


Online Services
, College Funding
, Long Term Planning
, Consultations
, Disability Income
, Institutional Services
, Wealth Management
, Corporate Services
, Retirement Planning
, Investment Services



 


Information

CONTACT INFORMATION
Phone: (310) 954-3200
Website: www.dafnacapital.com
ADDITIONAL INFORMATION:
Employee Size: 1 To 4
Exact Employee Count: 3
Exact Sales Volume: 290000
Location Type: Single Location
Sales Volume: 0 - 500K
CATEGORIES:


Portfolio Management & Investment Services
Finance
Investments & Securities



People Also Viewed


Harvest Asset Management Inc


3530 Wilshire Blvd Ste 1850 Los Angeles, California 90010




Provision Investments


3807 Wilshire Blvd  Los Angeles, California 90010




Kim Oak


4055 Wilshire Blvd  Los Angeles, California 90010




Visionquest Technology Ventures, Llc


5225 Wilshire Blvd Ste 1000 Los Angeles, California 90036




JMG Capital


11601 Wilshire Blvd 2180 Ste Los Angeles, California 90025




First Financial


11766 Wilshire Blvd Ste 300 Los Angeles, California 90025





Reviews

Add


You must Sign in to post reviews.





by  on 






Click here to be the first to review this business...



0 Reviews
 


Key Contacts




Daniel  Asher
PORTFOLIO MANAGER
Phone: (310) 724-5800 
 



Fariba  Ghodsian
MANAGER
Phone: (310) 724-5800 
 



Mandana  Hedayat
INVESTMENT OFFICER
Phone: (310) 724-5800 
 



David  Fischel
ASSOCIATE
Phone: (310) 724-5800 
 



John  Scola
HEAD TRADER
Phone: (310) 724-5800 
 



Terra  Fuller
RESEARCH ANALYST
Phone: (310) 724-5800 
 



View More
 























 






Site Map
FAQ
Privacy Policy
Terms of Use
About
Partners
Chamber Partner Program
Chamber Member Benefits




Top Cities:
Atlanta
Bronx
Brooklyn
Chicago
Cleveland
Dallas
Denver
Detroit
Houston
Las Vegas
Los Angeles
Miami
Minneapolis
New York
Philadelphia
Phoenix
Saint Louis
San Antonio
San Diego
San Jose


© 2017 CHAMBEROFCOMMERCE.COM














DAFNA Capital Management, LLC | Life Science Investment Fund



































Dafna Capital Management Company Profile | Financial Information, Competitors and ExecutivesCATEGORIESCITIESSign InFind Companies > Dafna Capital ManagementDafna Capital ManagementcbEDITcbLocationLos Angeles, CARevenue$6mTotal Funding$âFounded1999Employees7StageprivateCompany Websitedafnacapital.com/LinkedInlinkedin.com/Dafna Capital ManagementDAFNA Capital Management, LLC, a Los Angeles based SEC registered investment
advisor, specializes in managing long/short portfolios of predominantly publicly
traded biotechnology and medical device companies. Founded in 1999, for over 17
years we have merged unparalleled expertise, intellectual curiosity, and
investment rigor to fund the future of medicine and prudently manage the wealth
entrusted with us by our investorsKeywordsinvestment management,biotechnology,capital,fund,healthcareDafna Capital Management CompetitorsIndia Venture PartnersIndia Venture Partners is a financial services company based out of Calle...Aravis VenturesAravis is the first independent Swiss on-shore private equity house...Panorama CapitalPanorama Capital - Life Sciences and Technology InvestorsSee 2 more with a free trialRecent News from Dafna Capital ManagementStart trial to view recent news about Dafna Capital Management.Request trialBusiness Data in your WorkflowSave time and work smarter with fresh data on companies, leads, and contactsLearn about DataFox APIs and Data324 5th Street 
San Francisco, CA 94107 (415) 969-2144info@datafox.comLinkedInTwitterDataFoxProductWho Benefits?CustomersCompanyBlogLearn MoreAccount-based MarketingSales Prospecting TipsSales Operations StrategyFastest-Growing Tech Companies By RegionTourSalesforce IntegrationSlack IntegrationChrome ExtensionDataFox APISupportEmail UsHelp CenterPrivacy PolicyTerms of Service






Da | DAFNA Capital Management LLC Portfolio - 2017 Stock Picks and Performances 





























Home




 Homepage


 Membership Levels


 Membership Data Coverage


 Complete Stock List


 Founder's Message


 The Book


 FREE Trial






Screeners


Value Screens 


 All-In-One Screener


 Industry Overview


 Ben Graham Net-Net


 Undervalued Predictable


 Buffett-Munger Screener


 Magic Formula (Greenblatt)


 Historical Low P/S List


 Historical Low P/B List


 Peter Lynch Screen


 High Short Interest


 52-Week/3Y/5Y Lows


 52-Week/3Y/5Y Highs


 Predictable Companies


 S&P 500 Grid


 Dividend Stocks


 Spin Off List




Downloads | Tools


  Excel Add-In GURUF


 Manual of Stocks™


 Download Financial Data


 Download Guru Portfolios


 Download Stock PDFs


 Download Insider Data


  API


 Mobile App




Strategies


 Performances


 Buffett-Munger


 Undervalued Predictable


 Low P/S


 Low P/B


 Broadest Owned


 Most Weighted






Gurus




 Latest Guru Picks


 Real Time Picks


 List of Gurus (Personalize)


 Gurus Portfolios


 Scoreboard


 Top 10 Holdings View


 Sector Picks


 International Picks


 Aggregated Portfolio


 Consensus Picks


 Guru Bargains


 Hot Picks


 Industry Trends


 Geographic Trend


 ETFs


 Options


 European Shorting






Insiders




 All Insiders


 CEO Buys/Sales


 CFO Buys/Sales


 Insider Cluster


 Guru+Insider Double Buys


 Triple Buys/Sales


 Insider Trends


 Canadian Insider


 Dutch Insider






Market


Market Valuation


 Economic Data


 Industry Overview


 Market-Cap/GDP Valuation


 Global Market Valuation


 Shiller P/E


 Shiller P/E By Sectors


 Buffett Assets Allocation




By Country


 USA


 Australia


 Canada


 China


 Germany


 India


 Japan


 UK


 More...






Articles


Articles


 Editor's Picks


 GuruFocus Research


 Value Ideas


 Interviews with Gurus


 Top Ranked


 Value Idea Contest


 Videos


 Following Authors




Submit Articles


 Writers Wanted


 Value Contest Winners


 Submit Articles Online


 My Articles






Conference




 Value Conference


 Speakers


 Location/Venue


 Register


 After Conference Gathering (Free Drinks)






Tutorials




 Tutorials & Webinars


 FAQ


 Contact Us






Log In




 Free Sign-up


 Log In


 7-Day Free Trial 






Subscribe




 Free Trial ($399/Year)


 Refer a Friend & Earn $50














Warren Buffett


Bruce Berkowitz


George Soros


Seth Klarman


David Tepper


John Paulson


David Einhorn


Mohnish Pabrai


Prem Watsa


Bill Ackman


Joel Greenblatt


Carl Icahn


Arnold Schneider


Arnold Van Den Berg


Barrow, Hanley, Mewhinney & Strauss


Bill Ackman


Bill Gates


Bill Nygren


Bruce Berkowitz


Carl Icahn


Full Gurus List




Gurus List





Search
Compare

Search ▾










Get 7-Day Free Trial



My Portfolios▾
                        
Portfolios Overview
Create New Portfolio
Portfolio Contest


My Gurus▾
                        
Quick Browse
Personalize

My Gurus

Premium Gurus 
Premium Plus Investors 























DAFNA Capital Management LLC 

                Last Update: 05-15-2017 
            





                    Number of Stocks: 68

                    Number of New Stocks: 18




                    Total Value: $113 Mil

                    Q/Q Turnover: 22%


Countries:
                
 











This content requires JavaScript.

Details: Top Buys | Top Sales | Top Holdings  Embed:  



Bookmark

Print


Tweet















Bookmark Name:









			This page was added to your Bookmark.
		



Members Only. Please Sign Up or Log In first.




			Bookmark of this page has been deleted.
		




Add to Personalized Guru List
Remove from Personalized Guru List
RSS Update




LatestStock PicksCurrent PortfolioProfile/PerformanceSector Weighting




DAFNA Capital Management LLC has been successfully added into your Personalized Guru List.
        



DAFNA Capital Management LLC has been removed from your Personalized Guru List.
        



            This feature is only available for Premium Members, please sign up for
            GuruFocus Premium Membership

7-Day Free Trial Now





DAFNA Capital Management LLC has been successfully added into Guru Email Alerts list.
        



DAFNA Capital Management LLC has been removed from Guru Email Alerts list.
        



This feature is only available for Members, please Sign Up for FREE membership.
                If you have already signed up, please Log In






DAFNA Capital Management LLC's Portfolio is for Premium Plus  Membership subscribers only.

	
	GuruFocus Premium Plus  Membership
(This is a new feature)


 Gain access to the portfolios and trades of ALL 13F filers
 Their trading history
 Aggregated portfolio of any combinations among them
 Email alerts
 Excel Add-in for fully customized data downloads and research
 API for Guru/Insider data downloads (Realtime & historical)


7-Day Free Trial
Learn more








Add Notes, CommentsIf you want to ask a question or report a bug, please create a support ticket.






Select portfolio(s):








                        Create a new portfolio



Why you are interested?



            Your selection and notes will be stored in your portfolio.
        


Login to add portfolio















Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
                    | Earn affiliate commissions by embedding GuruFocus Charts

                                                GuruFocus Affiliate Program: Earn up to $400 per referral.  ( Learn More) 













Home  About   Jobs    Advertise    Site Map    Term of Use    Privacy Policy     RSS    Mobile App     Email Alerts    Referral Program    Affiliate Program    FAQ    Contact Us
                               

                © 2004-2017                GuruFocus.com, LLC. All Rights Reserved.
            


                    Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC.



                    Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.


















GF Chat {{numOfNotice}}




























×
Manage BookMarks





Close








FEEDBACK



















Nathan Fischel, Dafna Capital Management LLC: Profile & Biography - Bloomberg


































































  



























Feedback





Nathan Fischel

CEO/Portfolio Mgr/Founder,
Dafna Capital Management LLC






Career History




Fund Manager
Dafna LP-Lifesci Select-C, 1/2004-PRESENT


Fund Manager
Dafna Lifescience Market Neutral Ltd, 1/2003-PRESENT


CEO/Portfolio Mgr/Founder
Dafna Capital Management LLC, 1/1999-PRESENT


Fund Manager
Dafna LP-Lifescience-A, 1/1999-PRESENT


Professor Emeritus
University of California Los Angeles, PRESENT


Professor:Pediatrics
UCLA School of Medicine, FORMER


Dir:Molecular Hematology
Cedars-Sinai Medical Center, FORMER



Hadassah Hospital, FORMER


Show More







Corporate Information
Address:



Phone:
-


Fax:
-











From The Web












Awards & Publications



Certificates




Chartered Financial Analyst (CFA)









Memberships



Board Memberships




Stereotaxis Inc


Board Member, 2/2017-PRESENT









Sponsored Financial Commentaries







More From The Web


















Home


News


Top Headlines
Most Popular
Exclusive
Law
Entrepreneurs
Leaders
Economy
Environment
Science
Sports
Markets Magazine
Pursuits Magazine
Bloomberg Visual Data
Bloomberg Best (and Worst)
For comments or complaints about news coverage click here


Regions
U.S.
China
Europe
Asia
U.K. & Ireland
Australia & New Zealand
Canada
India & Pakistan
Japan
Africa
Eastern Europe
Latin America
Middle East
Markets
Commodities
Currencies
Bonds
Stocks
Energy Markets
Municipal Bonds
Emerging Markets
Funds
Islamic Finance
Industries
Energy
Technology
Real Estate
Finance
Health Care
Transportation
Insurance
Retail
Media
Manufacturing




Quick


Market Data


Stocks
Stock Futures
World Indexes
Americas
Europe, Middle East, & Africa
Asia-Pacific
Gainers & Losers
Earnings Calendar
Industry Leaders
Currencies
Americas
Europe, Middle East, & Africa
Asia-Pacific
Foreign Exchange Cross Rates
FX Fixings
Currency Converter
Forex Trading Videos
Commodities
Energy Prices
Metals Prices
Agricultural Prices


Rates & Bonds
US Treasuries
UK Gilts
Germany Bunds
Japan Bonds
Australia Bonds
Bloomberg Bond Indexes
Corporate Bonds
Consumer Rates
Economic Calendar
Watchlist
European Debt Crisis
Symbol Search
The Market Now




Personal Finance


Top Headlines
Saving & Investing
Real Estate
Retirement Planning
Financial Advisers
Taxes
Blog: Ventured & Gained
Real Cost Of
Money Gallery
Calculators
Watchlist (Portfolio Tracker)




Tech


Top Headlines
Social Media
Mobile & Wireless
Web
Enterprise Tech
TV, Games & Movies
Apple
Tech Deals
Global Tech
Slideshows
Videos




U.S. Politics


Sustainability


Top Headlines
Energy
Corporate Sustainability
Policy
Natural Resources
Health & Population
Slideshows
Videos
Blog: The Grid




Luxury


Top Headlines
Autos
Billionaires
Living
Property
Travel
Well Spent
Loot Blog
Pursuits Magazine
Videos




TV


Live TV
Channel Finder
Personalities
Apple TV
iPad App
Schedule
U.S.
Asia
Europe


Shows
Surveillance
Market Makers
Lunch Money
Street Smart
Bloomberg West
Game Changers




Video


Must See
Latest
Live TV
Shows
Playlist




Radio


Live Radio
Shows
Schedule
Personalities
Podcasts
Bloomberg Brief
Featured Podcasts and New Shows
Bloomberg View
Masters in Business
First Word
Surveillance
Bloomberg Advantage
In the Loop
Bloomberg Law
Taking Stock
Bloomberg Best
More Podcasts




Blogs


Global Tech
The Grid
Loot
The Market Now
Political Capital
Tech Deals
Ventured and Gained




Opinion




My Saved



Registration



Sign In



Bloomberg.com



Businessweek.com



Company



About
Blog
Careers
Diversity & Inclusion
News Mission
Philanthropy & Engagement
Press Room
Procurement
Sustainability




Products



Financial Products
Bloomberg Professional Service
Bloomberg Anywhere
Bloomberg Tradebook
Bloomberg Briefs
Bloomberg Indexes
Bloomberg SEF
Service Center
Customer Support
Enterprise Products
Enterprise Solutions
Trading Solutions
Industry Products
Bloomberg BNA
Bloomberg Government
Bloomberg Law
Bloomberg Link
Bloomberg New Energy Finance
Bloomberg Sports
Content Licensing




Bloomberg Anywhere



Mobile Apps



Bloomberg Visual Data











































DAFNA CAPITAL MANAGEMENT LLC Institutional Portfolio - NASDAQ.com






























































Hot Topics:
ETFs |
Smart Portfolio |
Currencies |
Online Broker Center















Search






















Home > 
	Quotes > 
	Ownership & Insider Trades > 
    Institutional Portfolio






DAFNA CAPITAL MANAGEMENT LLC






10990 WILSHIRE BOULEVARD, LOS ANGELES,  California, 90024, (310) 954-3200


Report Date: 03/31/2017

Position Statistics


Total Positions
78


New Positions
18


Increased Positions
30


Decreased Positions
33


Positions with Activity
63


Sold Out Positions
11


Total Mkt Value (in $ millions)
123



Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission.



Sector Weighting



Energy



Basic Materials



Industrials



Consumer Cyclicals



Consumer Non-Cyclicals



Financials
2.31%


Healthcare
97.69%


Technology



Telecommunication Services



Utilities










Total Positions




New




Increased




Decreased




Activity




Sold Out






78 Positions as of 03/31/2017


Company

Class

Value of Shares ($1,000s) ▼

Change in Value ($1,000s)

Change (%)

Shares Held



LOXO ONCOLOGY INC
COM
22,389
11,986
115.23
300,722


ATRICURE INC
COM
11,731
-278
(2.31)
506,946


BEIGENE LTD
SPONSORED ADR
5,786
-2,750
(32.22)
81,231


NXSTAGE MEDICAL INC
COM
5,250
-486
(8.47)
216,119


BLUEPRINT MEDICINES CORP
COM
4,600
558
13.79
82,500


INSULET CORP
COM
3,380
-532
(13.61)
63,484


GALAPAGOS NV
SPON ADR
2,929
-2,544
(46.48)
35,359


NEUROCRINE BIOSCIENCES INC
COM
2,867
-368
(11.36)
58,508


ISHARES TR
NASDAQ BIOTECH
2,835

New
8,700


BIOCRYST PHARMACEUTICALS
COM
2,722
2,390
721.14
541,128


BIOTELEMETRY INC
COM
2,629

New
75,000


AERIE PHARMACEUTICALS INC
COM
2,558
-2,823
(52.46)
46,770


SPECTRANETICS CORP
COM
2,522

New
65,496


ALDER BIOPHARMACEUTICALS INC
COM
2,475

New
221,013


SUNESIS PHARMACEUTICALS INC
COM PAR
2,334
-716
(23.47)
867,529


IMMUNOMEDICS INC
COM
2,223
-2,702
(54.87)
252,574


RADIUS HEALTH INC
COM NEW
2,117
-219
(9.37)
48,809


APPLIED GENETIC TECHNOL CORP
COM
2,096
636
43.56
411,000


MACROGENICS INC
COM
2,072
521
33.63
119,200


CELLECTIS S A
SPONSORED ADS
1,983
1,983
New
76,404




<< first< previous1234next >last >>








Latest News Headlines




                            DSP Group to Participate at the Canaccord Genuity Growth Conference
                        



	                     7:00AM ET  - GlobeNewswire
	                




                            KVH Industries to Host Second Quarter Conference Call on August 2, 2017
                        



	                     7:00AM ET  - GlobeNewswire
	                




                            WisdomTree Announces Second Quarter 2017 Results
                        



	                     7:00AM ET  - GlobeNewswire
	                




                            Cesca Therapeutics Announces Issuance of New Cellular Processing Patent Poised to Revolutionize CAR
                        



	                     7:00AM ET  - GlobeNewswire
	                




                            Merck profit soars 61.5 pct as Keytruda sales surge
                        



	                     6:51AM ET  - Reuters
	                





View All Latest Headlines



































CLOSEX

Edit Favorites

Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.






Update

Clear List







CLOSEX
Customize your NASDAQ.com experience
Background Color Selector

Select the background color of your choice:





 Black
							





 Slate Gray
							






 Light Gray
							





 Gray Blue
							






Quote Search

Select a default target page for your quote search:



						 Real-Time

						 After Hours

						 Pre-Market
 News
					


						 Flash Quote

						 Summary Quote

						 Interactive Charts

						 Default Setting




					Please note that once you make your selection, it will apply to all future visits to NASDAQ.com.
					If, at any time, you are interested in reverting to our default settings, please select Default Setting above.
					
					If you have any questions or encounter any issues in changing your default settings, please email isfeedback@nasdaq.com.
				





CLOSEX
Please confirm your selection:

					You have selected to change your default setting for the Quote Search. This will now be your default target page;
					unless you change your configuration again, or you delete your
					cookies. Are you sure you want to change your settings?


YES
NO













CLOSEX


Please disable your ad blocker (or update your settings to ensure that javascript and cookies are enabled), so that we can continue to provide you with the first-rate market news and data you've come to expect from us.





CLOSEX



































DAFNA CAPITAL MANAGEMENT, LLC - Financial Diligence Networks






























☰



s 






0

    B
  


Notifications


You do not have any new notifications





0

    3
  


Connections


Loading...


See All




0

    5
  


Messages
Jcompose


Loading...


See All







Anonymous User






Anonymous User




⚙Settings
 


?Help
 


LSign out
 



⚙

Settings



L 
Sign out











 


DAFNA CAPITAL MANAGEMENT, LLC
 









Documents




DAFNA CAPITAL MANAGEMENT, LLC



Sign in to access tags

Asset Manager
Founded in Hidden

dHidden
gHidden
oHidden


Headcount: Hidden

Assets Under Management:
Hidden






Headquarters





Point of Contact













DAFNA CAPITAL MANAGEMENT, LLC's Posts
Sign in to see all of DAFNA CAPITAL MANAGEMENT, LLC's posts and to be notified of new updates.
Sign in

 
Sunshine out of the shadows with promising heart device


      "(Heart devices) is an area of medicine that's entering its more revolutionary phase," said David Fischel, a principal at Los Angeles-based Dafna Capital Management LLC, Sunshine's second-largest investor. Fischel, who also has holdings in Canada-based ...
    

      Read More >
 Reuters
July 12, 2012



 Report
 
Report inappropriate or irrelevant content





Four Biotech Names with Major Market Potential: Michael Higgins


      He has worked as an analyst with Dafna Capital Management LLC, Wedbush Securities and an independent research firm he founded, 4sight Research Partners LLP. Higgins has earned a four-star rating from StarMine for stock recommendation performance.
    

      Read More >
 Trefis
December 20, 2012



 Report
 
Report inappropriate or irrelevant content





Protalix hires Citigroup to examine sale options


      On the other hand, US hedge fund Dafna Capital Management LLC (an investor in Protalix) managing member Dr. Fariba Ghodisan observes that recent deals in the pharmaceutical market reflect a large appetite by major pharmaceutical firms for the acquisition ...
    

      Read More >
 globes.co.il
February  5, 2013



 Report
 
Report inappropriate or irrelevant content





Four Biotech Names with Major Market Potential: Michael Higgins


      Four Biotech Names with Major Market Potential: Michael Higgins join login services submit news ... Funding Four Biotech Names with Major Market Potential: Michael Higgins Source: George S. Mack of The Life Sciences Report Category: Investment, Biotech
    

      Read More >
 investorideas.com
December 19, 2012



 Report
 
Report inappropriate or irrelevant content





PlacementTracker Publishes Most Active PIPE Investors in First Half of 2013


      Legal counsel rankings exclude all 144-A Offerings, Equity Lines of Credit, At the Market Transactions, Rights Offerings, Bought Deals, and all PIPE transactions conducted by foreign issuers that trade in the U.S. on the Pink Sheets. Data is for closed ...
    

      Read More >
 GlobeNewswire
July 10, 2013



 Report
 
Report inappropriate or irrelevant content





PlacementTracker Publishes Third Quarter 2014 PIPE Market League Tables


      Legal counsel rankings exclude all 144-A Offerings, Equity Lines of Credit, At the Market Transactions, Rights Offerings, Bought Deals, and all PIPE transactions conducted by foreign issuers that trade in the U.S. on the Pink Sheets. Data is for closed ...
    

      Read More >
 StreetInsider
October  8, 2014



 Report
 
Report inappropriate or irrelevant content





PlacementTracker Publishes First Half 2015 PIPE Market League Tables


      Investment Banking rankings exclude all 144-A Offerings, Equity Lines of Credit, At the Market Transactions, Rights Offerings, Bought Deals, and all PIPE transactions conducted by foreign issuers that trade in the U.S. on the Pink Sheets. On transactions ...
    

      Read More >
 Market Watch
July  8, 2015



 Report
 
Report inappropriate or irrelevant content





PlacementTracker Publishes First Half 2015 PIPE Market League Tables


      Legal counsel rankings exclude all 144-A Offerings, Equity Lines of Credit, At the Market Transactions, Rights Offerings, Bought Deals, and all PIPE transactions conducted by foreign issuers that trade in the U.S. on the Pink Sheets. Data is for closed ...
    

      Read More >
 Benzinga
July  8, 2015



 Report
 
Report inappropriate or irrelevant content





DAFNA CAPITAL MANAGEMENT LLC


      Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages. Please note that once you make your selection, it will apply to all future visits to NASDAQ.com.
    

      Read More >
 NASDAQ
June 29, 2015



 Report
 
Report inappropriate or irrelevant content





Daniel B. Asher


      Mr. Asher earned his B.G.S. with an emphasis in Econometrics from the University of Michigan in 1978. To contact Dafna Capital Management LLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.
    

      Read More >
 Bloomberg
September  2, 2015



 Report
 
Report inappropriate or irrelevant content





PRECISION OPTICS CORPORATION INC


      Precision Optics Corp., engages in designing, developing, manufacturing and selling of optical system and components, optical thin-film coatings, and medical devices. Its products and services fall into two areas: medical products for use by hospitals and ...
    

      Read More >
 4 Traders
August 27, 2015



 Report
 
Report inappropriate or irrelevant content





PlacementTracker Publishes 2014 PIPE Market League Tables


      Data is for closed and definitive agreement transactions reported as of 1/06/15. PlacementTracker, a flagship product of Sagient Research Systems, is well recognized as the leading provider of research, data, and analytics covering the PIPE market (Private ...
    

      Read More >
 GlobeNewswire
January  7, 2015



 Report
 
Report inappropriate or irrelevant content





Stereotaxis, The Next Intuitive Surgical - From A Large Shareholder's Perspective


      However, based on questions from my readers, I arranged an interview with David Fischel, Principal at DAFNA Capital Management, LLC, an investment management ... comes across in my mind as a very attractive acquisition candidate in providing both short ...
    

      Read More >
 Seeking Alpha
August 27, 2013



 Report
 
Report inappropriate or irrelevant content





Women of the Street’—Not Just Another War Story


      KPS Capital Partners LP; and, Deborah Harmon, Co-founder and CEO, Artemis Real Estate Partners. She concludes her interviews with two women who have had both big bank and entrepreneurial experience in the world of funds of funds, Kelly Chesney and Connie ...
    

      Read More >
 allaboutalpha.com
July 21, 2015



 Report
 
Report inappropriate or irrelevant content





Biotech's Rally Fuels Bubble Fears


      “You have to be somewhat optimistic to justify some of the valuations, but the excitement overall is justified,” said Dr. Nathan Fischel, who runs Dafna Capital Management LLC, a $170 million hedge fund in Los Angeles focused on biotech and medical ...
    

      Read More >
 MSN
March 24, 2015



 Report
 
Report inappropriate or irrelevant content





PlacementTracker Publishes First Half 2015 PIPE Market League Tables


      Legal counsel rankings exclude all 144-A Offerings, Equity Lines of Credit, At the Market Transactions, Rights Offerings, Bought Deals, and all PIPE transactions conducted by foreign issuers that trade in the U.S. on the Pink Sheets. Data is for closed and ...
    

      Read More >
 IT Business Net
July  8, 2015



 Report
 
Report inappropriate or irrelevant content





Book Review: 'Women Of The Street' - Not Just Another War Story


      Jones talks public equities investing with Leah Zell, founder and principal, Lizard Investors; Thrya Zerhusen, founder, Fairpointe Capital; Fran Tuite, portfolio manager, RMB Capital Management LLC and Dr. Farriba Fischel Ghodsian, CIO, DAFNA Capital ...
    

      Read More >
 Seeking Alpha
August 13, 2015



 Report
 
Report inappropriate or irrelevant content





Biotech’s Rally Fuels Bubble Fears


      Nasdaq bubble fears are back. But this time around, the biggest dangers may not involve technology stocks. Instead, some investors are looking askance at biotechnology stocks, a sector that wasn’t nearly as developed when the Nasdaq Composite Index set ...
    

      Read More >
 Wall Street Journal
March 24, 2015



 Report
 
Report inappropriate or irrelevant content





Fred Goldman CPA


      Prior to joining the firm, he was the Chief Financial Officer at Dafna Capital Management LLC (alternately Castle Creek LifeScience Partners, LLC). Mr. Goldman served as the Chief Financial Officer of the Kessler Asher Group and certain of its affiliates.
    

      Read More >
 Bloomberg
November 10, 2015



 Report
 
Report inappropriate or irrelevant content





PROZONE INTU PROPERTIES LTD


      Engages in the business of designing, developing, owning and operating of shopping malls, commercial and residential premises Prozone Capital Shopping Centres Ltd. engages in the business of designing, developing, owning and operating of shopping malls ...
    

      Read More >
 4 Traders
September 13, 2007



 Report
 
Report inappropriate or irrelevant content





PlacementTracker Publishes Third Quarter 2015 PIPE Market League Tables


      PlacementTracker, the leading source for data and analysis to institutions in the PIPE market, today announced the most active investment banks, investors, and law firms in the U.S. PIPE market through the third quarter of 2015. Through the end of Q3, a ...
    

      Read More >
 Yahoo Finance
October  7, 2015



 Report
 
Report inappropriate or irrelevant content




No news for DAFNA CAPITAL MANAGEMENT, LLC right now. Check back soon!


            Powered by 



DAFNA CAPITAL MANAGEMENT, LLC's Important Information
Sign in to see all of DAFNA CAPITAL MANAGEMENT, LLC's info like historical assets, fund info, performance, terms, and other important info normally found in a DDQ.
Sign in


DAFNA CAPITAL MANAGEMENT, LLC's Employees
Sign in to see all of DAFNA CAPITAL MANAGEMENT, LLC's important employee info, such as senior management's bios' education, and responsibilities.
Sign in


DAFNA CAPITAL MANAGEMENT, LLC's Offices
Sign in to see all of DAFNA CAPITAL MANAGEMENT, LLC's offices.
Sign in







★Follow✓Following☆Unfollow

More Actions
GSave as PDF
CPrint
















Loading...


Loading...







 Dafna Capital Management LLC, Nathan  Fischel,  























  A publisher of Business Information since 1983    



  









 
            





Search Business
		    
				Search Executive
		    

        

  Advanced Search








 
                 




 | 
		 
						
   							Sign In
   					
			 | 
	    Hints





    







Company Name
Dafna Capital Management LLC
 
 














 Address

	        
				
						10990 Wilshare Blvd.		        	
				
							Ste. 1400		        	
					
							
						
	        
					
			
					
					 	
					 		Losangeles,
					 		
					 
					 
					 
					
           					 California
           			
	    			
	    			
         					90024
         					
	    				
	    			
	    					
	    				
	    			
	    			         		
	    			
	    				
	       				 United States
						         
				



Email
  info@dafnacapital.com
Phone
 1-310-724-5800


Website


							        www.d3capital.com
							        

Fax

							         1-310-481-0722














            Summary            
      Executive Details      
       Board Members       









Business Information
															The group's principal activity is to provide capital management services. The group provides biotechnology stocks, REITs, convertibles, mutual funds, ETFs, and bonds. The group operates from the United States.   
															






                       
																Executive Information                                                                
															



																Name

																Title
															

																Email
															

Treea FullerResearch Analyst N/A  Nathan FischelFounder, Principal, CEO N/A  Fariba GhodsianPrincipal, Chief Investment Officer N/A  Mandana HedayatChief Compliance Officer, Dir. - Risk Management N/A  Xun LinController N/A  

 
												



 
									Company Size
								

  Sales Range Below 10 Millon    Employee Range  Below 25
   

 
											
										
										  

TO SEE COMPLETE RESULTS SUBSCRIBE NOW
TO SEE COMPLETE RESULTS SUBSCRIBE NOW



Click for more Executives 


















       Financial Summary       
        Income Statement        
         Balance Sheet         
         Cash Flows         
          Ratios          







































                                              FOR SUBSCRIBERS ONLYCLICK HERE TO
                                              
                                              SUBSCRIBE NOW































           
 
 
Home   |   About Us   |   Product Information    |   Subscription   |  List Builder    |  Executive List    |   Email Lists      |  Contact Us   |   Site Map   |  
 Browse Directory    




 

 &nbsp   ©
 2009, Walkers's Research - A publisher of Business Information since 1983, All Rights Reserved.

  



